Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Kidney Function Tests Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Published

on

<!– Name:DistributionId Value:8753322 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1199811 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:3e49d50a-c1d4-4e56-916f-0c71b45fdd12 –>

New York, Feb. 21, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Kidney Function Tests Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028” – https://www.reportlinker.com/p06421129/?utm_source=GNW
Global kidney function tests market was valued over USD 862 million in 2022 and is forecast to grow at a CAGR of 9.71% through 2028. The growth of the global market for kidney function tests is anticipated to be supported by an increase in awareness of diagnostic techniques for kidney function. The growing global burden of chronic kidney disease is attributed in huge share to diabetes and high blood pressure. In the upcoming years, rising diabetes rates will have an effect on market expansion. The International Diabetes Atlas’ tenth edition estimates that 537 million adults (20-79 years old), or one in ten people, had diabetes in 2021. It is anticipated that this number will increase to 643 million by 2030 and 783 million by 2045. Kidneys are among the most vital organs of the human body. Kidneys acts as blood filters, reabsorbing the essential elements and removing the water-soluble waste products from the blood. Hence, they require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, otherwise they become vulnerable to cancerous tumors and metastasis. The functional damage of the kidney is common across the world and its incidents are increasing at a rapid pace. The symptoms which indicate a problem related to kidneys include high blood pressure, blood in urine, difficulty in urination, frequent urges to urinate, and swelling in the hands and feet due to a buildup of fluids in the body.

Rising Prevalence of Kidney Disorders and Diseases
The growing occurrence of several kidney disorders such as acquired cystic kidney disease, amyloidosis & kidney disease, diabetes insipidus, ectopic kidney, glomerular diseases, anti-GBM (Goodpasture’s) disease, IgA nephropathy, among others have drastically increased the number of patients which requires accurate diagnosis and proper treatment.This, in turn, is expected to drive the growth of the global kidney function tests market.

Furthermore, acute kidney injury (AKI), also known as acute renal failure or acute kidney injury, is very common in patients who are in hospitals. Acute kidney injury (AKI) affects more than 13 million people and results in 1.7 million deaths every year across the globe. Owing to the rising incidences of kidney diseases and disorders, the demand for early diagnosis and treatments is expected to surge, which bolsters the growth of the market. For instance, according to the Centers for Disease Control and Prevention (CDC), 40% of people with rigorously reduced kidney function are not aware of having chronic kidney disease (CKD).

Technological Advancements
Rising adoption of advanced technology concerning diagnosis and treatment is expected to bolster the growth of the market.These continuous developments and innovations are providing better treatments to patients.

The latest trends in technology are using computer-based intelligent decision support systems (DSS) and expert systems, which are used in dialysis and are based on genetic algorithms and artificial neural networks (ANN).Also, the increase in interest in the internet of things (IoT), deep learning, an expanded and complex version of shallow ANN, is being used in the medical field.

These advancements help in image diagnosis, alerting systems, and diagnostic assistance.

Increase in the Prevalence of Diabetes and Hypertension
The growing occurrences of underlying conditions such as diabetes and hypertension among the masses have significantly increased the demand for getting diagnoses and treatments done for these chronic diseases.This, in turn, is expected to positively influence the growth of the global kidney function tests market.

According to the Centers for Disease Control and Prevention (CDC), in 2019, there are approximately 37.3 million people who have diabetes, accounting for 11.3% of the US population. Out of these, 28.7 million people are diagnosed, and 8.5 million people are undiagnosed. Rising geriatric population is more prone to kidney diseases and kidney failures as aging increases the risk of chronic diseases such as diabetes and hypertension. The increase in the number of elders suffering from diabetes and hypertension is surging the demand for kidney function tests, as kidney disorders and kidney failures are caused by these chronic diseases. Therefore, owing to the rising prevalence of diabetes and hypertension, there is a surge in the number of cases of Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI), which in turn, is facilitating the growth of the market.
Recent Developments
• In 2019, Fresenius Medical Care received breakthrough device designation by the U.S. FDA for its most recent hemodialysis machine, whose objective is to stop blood clotting without using any medication
• Similarly, in 2019, CareDx announced the new model built for kidney transplants. It has included Predicted artificial intelligence (AI) for individuals who are suffering from chronic kidney diseases (CKD).
• Recently, in 2022, bioMérieux received United States Food and Drug Administration (US FDA) authorization for the innovative VIDAS NEPHROCHECK assay to detect kidney stress in individuals who are at risk of acute kidney injury (AKI).

Market Segmentation
Global kidney function tests market segmentation is based on type, component, end user, regional distribution, and competitional landscape.Based on type, the market is divided into urine tests, blood tests and others.

Urine tests are further subcategorized into Urine Protein Tests, Creatinine Clearance Tests, Microalbumin Tests.Blood tests are further categorized into Serum Creatinine Tests, Glomerular Filtration Rate Tests, Blood Urea Nitrogen Tests.

Based on component, the market is categorized into Dipsticks, Reagents, Kits & Assays, and Others.Based on end user, the market is further bifurcated into Hospitals & Clinics, Diagnostic Laboratories, and others.

In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising cases of renal disorders.
Market Players
Baxter International Inc., Abbott Laboratories, Inc., Sysmex Corporation., F. Hoffmann-La Roche Ltd., Danaher Corporation., URIT Medical Electronic Co. Ltd., Nova Biomedical Corporation., Laboratory Corporation of America Holdings., Siemens Healthineers., ARKRAY Inc., IDEXX Laboratories, Inc., Fresenius SE & Co. KGaA., Cook Group., ACON Laboratories, Inc, and Randox Laboratories Ltd. are some of the leading companies operating in the market.

Report Scope:

In this report, global kidney function tests market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Kidney Function Tests Market, By Type:
o Urine Tests
Urine Protein Tests
Creatinine Clearance Tests
Microalbumin Tests
o Blood Tests
Serum Creatinine Tests
Glomerular Filtration Rate Tests
Blood Urea Nitrogen Tests
o Others
• Kidney Function Tests Market, By Component:
o Dipsticks
o Reagents
o Kits & Assays
o Others
• Kidney Function Tests Market, By End User:
o Hospitals & Clinics
o Diagnostic Laboratories
o Others
• Kidney Function Tests Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
Germany
United Kingdom
Netherlands
Sweden
Italy
Spain
o Asia-Pacific
China
Japan
Singapore
India
South Korea
Australia
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
UAE
Saudi Arabia
South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Kidney Function Tests market

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06421129/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Announce Winner of Inaugural 2024 Life Sciences Innovation Summit

Published

on

jp.-morgan-life-sciences-private-capital,-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit

In conjunction with Abu Dhabi Global Healthcare Week 2024
ABU DHABI, UAE, May 17, 2024 /PRNewswire/ — J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Group announced today Rayees Rahman of Harmonic Discovery as the winner of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Harmonic Discovery is a precision pharmacology company applying its generative chemistry platform to advance next-generation kinase inhibitors.

In partnership with the Department of Health – Abu Dhabi (DoH), the Summit took place on May 14-15, 2024 at Cleveland Clinic Abu Dhabi and showcased the 11 innovative finalists, as well as highlighted existing innovators and opportunities in the Emirate of Abu Dhabi. The event also featured keynote speeches from Dr. Laurie Glimcher of Dana-Farber Cancer Institute, Dr. Shahrukh Hashmi of the Department of Health – Abu Dhabi, and Dr. David Ho of Columbia University Medical Center and provided attendees networking opportunities to gain valuable insights into the future of life sciences innovation. 
In addition, the jury designated Chun-Hao Huang of Algen Biotechnologies as honourable mention. Algen Biotechnologies is a platform therapeutics and drug discovery company using world-leading CRISPR and AI to find treatments for cancer, inflammation and metabolic diseases.
The winners were selected by an esteemed, international panel of judges, which included:Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer InstituteJorge Guzman, MD, CEO at Cleveland Clinic Abu DhabiProf. Shahrukh Khurshid Hashmi, MD, Director of Research, Department of Health, Abu DhabiYasmine Hayek Kobeissi, PhD, CQF, BSc., Executive Director at Blue Horizon AdvisorsAnya Schiess, Managing Partner at J.P. Morgan Life Sciences Private CapitalWalid Zaher, PhD, Co-Founder and CEO, Carexso
Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi said: “Under the directives of the UAE’s wise leadership, and renowned for its world-leading medical infrastructure, Abu Dhabi stands at the forefront of healthcare excellence, offering an unparalleled opportunity for advancement in healthcare for global partners. It was our utmost pleasure hosting the J.P. Morgan Asset Management Life Sciences Innovation Summit 2024 on the sidelines of Abu Dhabi Global Healthcare Week and we commend the winners for their pioneering efforts in driving impactful advancements in healthcare; their dedication to innovation not only transforms the landscape of medicine, but also holds the promise of improving lives worldwide.” 
Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are thrilled with the level of biotech passion and innovation that we observed at this year’s Summit in Abu Dhabi. The energy was truly palpable we are thrilled to announce Rayees Rahman as the winner of our first Life Sciences Innovation Summit. Harmonic Discovery’s approach embodies the next generation of drug discovery and development. We appreciate the time and effort of all participants and cannot wait for our next event in the region.”
Nabil Kobeissi, Chief Executive Officer of Blue Horizon Advisors, said: “As the main sponsor, we are committed to nurturing and fostering the growth of all 11 finalists in this vibrant biotech ecosystem. This Summit marks the beginning of a transformative journey, and we are confident that it will pave the way for a flourishing hub in the region. We are also pleased to announce that we will commit to invest in and partner with the winner, Harmonic Discovery, to support its future growth in the region.”
Sponsors for the event included J.P. Morgan Life Sciences Private Capital, J.P. Morgan Commercial Bank, Blue Horizon Advisors, United Al Saqer Group, Thermo Fisher Scientific, and Salam Capital. The Summit organisation, logistics and finalist recruitment were facilitated by Lyfebulb.
Of importance, at the Summit, Mr. Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City, announced that Masdar City Free Zone would award all 11 Finalists complimentary business licenses to further support their establishment in the region. Masdar City is one of the world’s most sustainable urban developments and innovation hubs with a growing focus on life science entrepreneurship in Abu Dhabi.

View original content:https://www.prnewswire.co.uk/news-releases/jp-morgan-life-sciences-private-capital-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit-302149186.html

Continue Reading

Artificial Intelligence

Congregating in the Lion City for a Win-Win Future of Intelligent Computing at the Global Data Center Facility Summit 2024

Published

on

congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024

SINGAPORE, May 17, 2024 /PRNewswire/ — On May 17, 2024, the Global Data Center Facility Summit 2024 was held in Singapore with the theme of “Power the Digital Era Forward.” At the summit, over 600 data center industry leaders, technical experts, and ecosystem partners gathered to discuss new trends and opportunities of the global data center industry in the intelligent computing era. The attendees also got to experience all-scenario, all-ecosystem, and all-service end-to-end (E2E) solutions, share innovative practices of green data centers in the Asia Pacific and Europe, and experience the exhibition vehicle to unveil the mystery of Outdoor PowerPOD that features one power system per container. By fully embracing the intelligent computing era, Huawei strives to power the digital era forward.

Seizing Opportunities Brought by AI and Jointly Building Green & Reliable Computing Infrastructure
At the opening speech, Charles Yang, Senior Vice President of Huawei and President of Marketing, Sales and Services, Huawei Digital Power, noted that since ChatGPT ushered in the AI era, large models keep pushing the limits of computing power and the intelligent computing industry is witnessing an unprecedented construction boom. As predicted, 100 GW will be added to the global data center installed capacity and the market value will exceed US$600 billion in the next five years.
According to Charles, with opportunities come challenges. The primary challenge concerning the data center industry is reliability and electricity. Data centers are scaling up from the MW-level to the GW-level. E2E reliability of data centers is becoming even more important than ever. In response to the opportunities, Huawei will work with customers and partners to expand the industry space.
Steering Data Centers to the AI Era with Product + Service + Ecosystem
During the summit, Sun Xiaofeng, President of Huawei Data Center Facility & Critical Power Business, delivered a speech titled “Power the Digital Era Forward. ” He stated that as AI large models are penetrating, the surging compute demands drive the expansive growth in data center.
To address the challenges, Huawei strives to build product + service + ecosystem E2E data center solutions that feature fast deployment, flexible cooling, green energy, and ultimate reliability.
Fast deployment: Data centers are fully modularized and prefabricated to ensure high quality and efficient construction.Flexible cooling: Air-liquid fusion and integrated cooling source emerges as the optimal cooling architecture for intelligent computing.Green energy: New generation-grid-load-storage integrated solution is built to ensure the sound operations of intelligent computing centers.Ultimate reliability: Data centers are safeguarded through reliable products and preventive protection.Currently, Huawei’s global service network covers more than 170 countries with over 1800 professional engineers, providing 24/7 technical support. With N+ flagship service centers, Huawei has built a one-hour service radius for its customers.
The ecosystem is a key part for a win-win future of intelligent computing. Huawei works with partners to develop comprehensive E2E solutions and provide customers with one-stop data center services.
During the summit, Huawei and the ASEAN Centre for Energy released a white paper on “Building Next Generation Data Center Facility in ASEAN.” The document provides insights into the status quo, challenges, and trends of data centers in the ASEAN region, and emphasizes that efficient and energy-saving products and solutions should be applied. It also proposes future-oriented policy recommendations for data center markets.
In the ecosystem exhibition area, Huawei showcased scenario-based solutions for large-, medium-, and small-sized data centers, and demonstrated data center consulting, design, integrated development, and delivery capabilities with dozens of ecosystem partners including CIMC, Weichai, CSCEC, and Huashi.
On a special note, the Huawei Outdoor PowerPOD exhibition vehicle made its global debut. The Huawei Outdoor PowerPOD features one power system per container, outdoor deployment, plug-and-play, and high protection rating and reliability. It has become the preferred choice for decoupling the power supply architecture.
A single tree cannot make a forest.
AI is presenting great opportunities. By delving into the industry, aggregating partner ecosystems, and making innovations applicable to transformations, Huawei will continue to help customers build reliable computing infrastructure, accelerating the industry to embrace AI and powering the digital era forward.
Photo – https://mma.prnewswire.com/media/2415818/Global_Data_Center_Facility_Summit_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024-302148973.html

Continue Reading

Artificial Intelligence

HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market

Published

on

hoya-group-company,-pentax-of-america,-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-u.s-market

WASHINGTON D.C., May 17, 2024 /PRNewswire/ — HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical) and MAGENTIQ-EYE Ltd., an AI medical device company, announced today their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and strategic partnerships.

Pending field trials and customer demonstrations to be conducted over the next several months, the companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO™ AI-assisted lesion detection device in the U.S.A. beginning October 1st, 2024. The system will be demonstrated at the upcoming Digestive Disease Week (DDW) in Washington D.C., U.S.A.
MAGENTIQ-COLO™ is a cutting-edge system for the detection of gastrointestinal lesions in colonoscopies. Successfully validated in an international multicenter, randomized, controlled trial (RCT) with 950 enrolled patients at 10 hospitals in Europe, United States and Israel, its outstanding diagnostic capabilities are setting new standards in endoscopic AI.
“We are excited to bring the MAGENTIQ-COLO™ device to the GI community in the U.S. Together with PENTAX Medical’s product portfolio, we are confident to provide a smart solution in colonoscopy and contribute further to colorectal cancer prevention”, says David Harrison, President PENTAX of America, Inc.
“Partnering with PENTAX Medical is an important milestone for us, as it opens new opportunities to introduce our game changing product to the U.S. market, benefiting doctors and their patients and saving more lives”, says Dror Zur, Founder & CEO of MAGENTIQ-EYE.
About MAGENTIQ-EYE Ltd.Founded in 2014, MAGENTIQ-EYE offers a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy, and saving more and more lives. www.magentiq.com 
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company’s mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community’s Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider’s experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support. Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles and helps improve endoscopy with smart innovations.
For more information: https://www.pentaxmedical.com
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of lifecare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels, and hard disk drives. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 36,000 people. For more information, please visit: https://www.hoya.com/en/

View original content:https://www.prnewswire.co.uk/news-releases/hoya-group-company-pentax-of-america-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-us-market-302148971.html

Continue Reading

Trending